Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rosiglitazone Clear all
Completed Phase 4 Interventional Results available

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

NCT00679939
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
21
States / cities
Tucson, Arizona • Huntington Park, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 24, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

NCT00612066
View directory record Official record
Conditions
Cushing's Disease
Interventions
rosiglitazone maleate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 4 Interventional

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

NCT00207402
View directory record Official record
Conditions
Hepatitis C
Interventions
rosiglitazone
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

NCT00348309
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
41
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

NCT00386100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd), Avandamet 8 mg/ 2000 mg (ttd), Metformin 500 mg (ttd), Metformin 1000 mg (ttd), Metformin 1500 mg (ttd), Metformin 2000 mg (ttd)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
71
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

NCT00399711
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
102
States / cities
Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

Rosiglitazone in Treating Patients With Liposarcoma

NCT00004180
View directory record Official record
Conditions
Sarcoma
Interventions
rosiglitazone maleate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Preferred Treatment of Type 1.5 Diabetes

NCT00194896
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, glyburide
Drug
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 69 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs

NCT00831129
View directory record Official record
Conditions
Pre-diabetes
Interventions
Rosiglitazone, Placebo Rosiglitazone, Simvastatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

NCT01174056
View directory record Official record
Conditions
Lung Inflammation
Interventions
Zileuton, Pioglitazone placebo, Zileuton placebo, Pioglitazone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

NCT00064727
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Avandia (Rosiglitazone), Avanclia (Rosiqlitazone)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 24, 2026, 4:42 PM EDT
Completed No phase listed Observational

Markers and Mechanisms of Vascular Disease in Type II Diabetes

NCT00256646
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Rosiglitazone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

NCT00381238
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Sun City, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

NCT00396227
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, thiazolidinedione (TZD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,665 participants
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 24, 2026, 4:42 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis

NCT00121953
View directory record Official record
Conditions
Endometriosis
Interventions
Rosiglitazone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

NCT00015691
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions
Metformin hydrochloride, Rosiglitazone maleate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 24, 2026, 4:42 PM EDT
Terminated Phase 3 Interventional

Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS

NCT00465296
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
rosiglitazone
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gene Regulation by Thiazolidinediones

NCT00567593
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Rosiglitazone
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 1 Interventional

Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome

NCT00006185
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Insulin Resistance
Interventions
Avandia administration for 6-12 weeks
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

NCT00511823
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
casopitant, dolasetron, granisetron, rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Results available

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

NCT01209143
View directory record Official record
Conditions
Solid Cancers
Interventions
Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL

NCT00178841
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
Interventions
Rosiglitazone and Bexarotene
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 24, 2026, 4:42 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

QTc Study of Rosi XR in Healthy Volunteers

NCT00884533
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosi XR, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 24, 2026, 4:42 PM EDT